Introduction
Arterial hypertension is a major risk factor for atherosclerosis, coronary artery disease, stroke, and chronic kidney disease, and is a prominent contributor to death worldwide. 1 It is estimated that a quarter of the world's adult population is hypertensive and this number is projected to rise to nearly 30% by 2025. 2 
frequency of hypertension, its cause in the majority of adults is unknown.
Hypertension is complex, with no single mechanism-sodium retention, renin release, and increased vascular tone-entirely explaining the blood pressure (BP) rise. The past 50 years have seen growing evidence implicating the immune system. 3 Recent data suggest that macrophages (M/) contribute to, and protect from, hypertension. Early studies in the spontaneously hypertensive rat 4 found a correlation between the distribution of sub-endothelial M/ and endothelial function, and that treatment with an angiotensin converting enzyme inhibitor improved endothelial function and reduced the number of vascular M/. Furthermore, many models of hypertension-angiotensin II (ANG II), high salt-are associated with renal accumulation of M/. 5, 6 Despite these and many other observational studies, few have attempted to modify M/ phenotype/number to examine their role in hypertension. [7] [8] [9] [10] Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor. 11 Its production is triggered by multiple stimuli including ANG II and pro-inflammatory cytokines. 12, 13 ET-1 acts by binding to two distinct receptors, the endothelin-A (ET A ) and the endothelin-B (ET B ) receptors. 14, 15 ET A and ET B receptors on vascular smooth muscle cell (VSMC) mediate the vasoconstrictor effects of ET-1. 16 ET B receptors are also found on vascular endothelial cells (EC) where their activation results in dilation. 17, 18 Production of vascular ET-1 is increased in some but not all animal models of hypertension. 19 Interestingly, ET antagonism can blunt BP elevation in ANG II infused rats suggesting that in this model, ET-1 largely mediates the hypertensive effects of ANG II. 20, 21 Importantly, a number of clinical studies have gone on to show the effectiveness of both selective ET A and mixed ET A/B antagonism in lowering BP in hypertension. [22] [23] [24] ET-1 is considered to be pro-inflammatory. ET A receptor activation is crucial in mediating the ANG II-induced infiltration of renal cortical T cells. 25 In both models of aldosterone-induced hypertension and diabetic nephropathy, selective ET A receptor antagonism reduced M/ infiltration, 26, 27 and in the diabetic model also reduced fibrosis. 27 However, the effects of ET-1 on M/ biology are not well studied. In the current studies, we explored the role of M/ and monocytes in mediating the pro-hypertensive effects of ET-1 and ANG II.
Methods
See Supplementary material online.
Results
Macrophages possess endothelin receptors but are not polarized by endothelin-1
We first found that mouse bone marrow-derived macrophages (BMDM) possess both ET A and ET B receptors (ET B > ET A ) although in relatively lower amounts than seen in VSMC and EC, respectively (see Supplementary material online, Figure S1 ). To examine the role of the M/ ET B receptor in greater detail, we generated novel mice deficient in ET B on myeloid cells alone (LysMET B -/-). These mice showed no differences in baseline vascular function or circulating immune cells compared with littermate controls (see Figure 1 and Supplementary material online, Figures S2-S4).
We then explored the ability of ET-1 to polarize BMDM. Increasing concentrations of ET-1 (10-10 4 pg/mL) were unable to polarize BMDM to a classical (M1) or alternative (M2) phenotype either alone or in combination (see Figure 2 and Supplementary material online, Figure S5 ). Furthermore, neither co-stimulation with LPS and ET-1 nor LPS stimulation following ET-1 priming, in the presence or absence of ET receptor blockade, augmented the BMDM response to LPS (see Supplementary material online, Figure S6 ).
BMDM stimulation with LPS/INFc (but not IL-4/IL-13) increased the media concentration of ET-1 at 24 h (see Supplementary material online, Figure S7 ), an effect that was blocked by phosphoramidon, an inhibitor of endothelin converting enzyme (ECE) which catalyzes the conversion of big ET-1 to the mature peptide. Thus, this increase in ET-1 likely represents de novo production.
Macrophages demonstrate chemokinesis to endothelin-1
Despite the lack of polarization by ET-1, BMDM demonstrated chemokinesis to ET-1. This effect was more apparent at higher concentrations of ET-1 and no different to MCP-1 at ET-1 10 3 pg/mL and 10 4 pg/mL. BMDM chemokinesis to ET-1 was blocked by both
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selective ET A (BQ123) and selective ET B (BQ788) receptor antagonism ( Figure 3A) . In terms of chemokinetic ability, LysMET B -/-BMDM had a blunted response to incremental concentrations of ET-1 compared with control BMDM, although the response to MCP-1 was maintained ( Figure 3B ).
Macrophages demonstrate endothelin-Bmediated endothelin-1 uptake
BMDM were then exposed to ET-1 10 pg/mL in their media. Serial assay of the media for ET-1 showed a gradual reduction over a 24 h period with the concentration at 24 h being approximately 60% that at baseline ( Figure 4A ). This reduction in media ET-1 was seen when BMDM were exposed to increasing concentrations of ET-1 ( Figure 4B ) and was not explained by degradation of the peptide over the 24 h period (see Supplementary material online, Figure S8 ). The fall in ET-1 was prevented by both selective antagonism of the ET B receptor (but not ET A ) as well as inhibition of dynamin-dependent endocytosis (see Figure 4C and Supplementary material online, Figure S9 ), supporting BMDM uptake of ET-1 through ET B receptor-mediated endocytosis. Neutral endopeptidase (NEP) inhibition had no effect. Additionally, mixed ET A/B receptor antagonism was no different to selective ET B blockade alone (see Supplementary material online, Figure S10 ). Further data to support the role of the M/ ET B receptor in clearing ET-1 were provided using an ET B gene silencing approach. M/ EDNRB knockdown again prevented ET-1 uptake by BMDM, an effect that was similar in magnitude to that seen with pharmacological ET B receptor antagonism ( Figure 4D) . As ET B receptors are also present on VSMC, we assessed their ability to remove ET-1 in vitro. VSMC did not remove ET-1 from their surrounding media ( Figure 4E) . BMDM from LysMET B -/and controls were also exposed to ET-1 for 24 h. As previously seen, control BMDM removed ET-1 from their medium, an effect that was blocked by BQ788. Medium from LysMET B -/-BMDM showed no difference in ET-1 concentration at 24 h compared with baseline and there was no effect of pre-treatment with BQ788 ( Figure 4F) . To further support our hypothesis of M/ ET-1 uptake, we exposed BMDM to fluorescent ET-1. Our results suggested a statistically significant (P < 0.01) increase in BMDM intracellular fluorescence following treatment with ET-1 ( Figure 4G ). Uptake of fluorescence was blocked by selective blockade of the ET B receptor and absent, as expected, in BMDM from LysMET B -/mice. Furthermore, this uptake process occurred rapidly ( Figure 4H ) and reached a steady state within 60 min.
Macrophages modify vascular contractility
The functional importance of M/ ET B receptor-mediated ET-1 uptake is demonstrated in Figure 5 . Here, we infused M/ into the myography bath 15 min prior to infusing ET-1. Increasing number of M/ significantly attenuated the vasoconstrictor actions of ET-1 (P < 0.001 vs. control); this effect was lost when the M/ were pre-treated with selective ET B receptor antagonism or when LysMET B -/-BMDM were infused. There was no effect of pre-treating M/ with a selective ET A receptor antagonist. M/ pre-treatment did not alter the contractile response to KCl. Again, these findings are in keeping with a rapid binding of ET-1 to M/ ET B that blunts its functional effects. Additionally, and as expected, ET-1 increased oxidative stress in mesenteric vessels; this effect was attenuated by M/ and attenuation was dependent on an unblocked ET B receptor. 
Human and mouse macrophages show similar responses to endothelin-1
As in mouse BMDM, human M/ showed expression of both the ET A and ET B receptor (see Supplementary material online, Figure 11A ). Similarly, human M/ were not polarized to a classical or alternative phenotype by ET-1 (see Supplementary material online, Table S1 and Figure S11B ) but showed evidence of ET B receptor-mediated ET-1 uptake and Figure S11C and D).
chemokinesis to ET-1 and (see Supplementary material online,

Macrophage depletion augments the pressor response to endothelin-1 but not angiotensin II
To understand the role of M/ in the pressor response to ET-1, we administered incremental doses of intravenous (i.v.) ET-1 to CD11b-DTR mice given diphtheria toxin (DT) and to controls. M/ depletion per se was not associated with a difference in baseline mean arterial pressure (MAP) ( Figure 6A ) or a shift in vasoconstrictorvasodilator capacity of conduit or resistance vessels (see Supplementary material online, Figure S12 ). Administration of ET-1 following M/ depletion resulted in an exaggerated hypertensive response compared with controls ( Figure 6B ) with a greater maximal change in mean arterial pressure (MAP) in M/-deficient mice ( Figure 6C) . At a dose of ET-1 1 nmol/kg the maximal change in MAP 
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Myeloid endothelin-B receptors in hypertension was approximately two-fold greater in M/ deficient mice compared with control groups. Notably, M/ depletion did not affect the acute pressor response to ANG II ( Figure 6D) .
To specifically explore the role of the M/ ET B receptor in the pressor response to ET-1, we administered i.v. ET-1 to LysMET B -/and control mice. Baseline MAP did not differ between the two groups ( Figure 6E) . Similar to the response seen following systemic M/ depletion, LysMET B -/mice demonstrated an exaggerated pressor response to ET-1 ( Figure 6F) . At a dose of ET-1 0.1 nmol/kg the maximal change in MAP was approximately two-fold that seen in control animals.
Macrophage depletion augments the chronic hypertensive response to endothelin-1 and adoptive transfer of wild type monocytes prevents this A 3-week infusion of ET-1 led to sustained increases in systolic and diastolic BP in CD11b-DTR mice ( Figure 7A and B) . Both systolic and diastolic BP increased by approximately 10-12 mmHg above baseline. DT was used to deplete M/ over a period of 7-10 days resulting in gradual increases in both systolic and diastolic BP ( Figure 7C and D) .
As the effects of DT weaned, and M/ repopulated, BP gradually returned to pre-depletion levels. The maximal increase in systolic BP was approximately 20 mmHg and for diastolic BP this was approximately 15 mmHg. In the negative control arm, CD11b-DTR mice were injected with phosphate buffered saline, and here, BP remained stable throughout the experiment.
In keeping with an important role for circulating monocytes in these effects, adoptive transfer of wild type monocytes prevented the rise in BP seen with DT ( Figure 7E and F) . As might be expected, M/ depletion was associated with a rise in circulating ET-1 with a fall to pre-depletion levels with M/ repopulation ( Figure 7G ).
Macrophage depletion augments the chronic hypertensive response to a high salt diet
Next, we explored the role of M/ in a second model of hypertension that associated with a high salt diet. High salt led to rises in both systolic and diastolic BP of approximately 10 mmHg above baseline (see Supplementary material online, Figure S13A ). M/ depletion led to further rises in both and, as previously seen, these effects diminished with M/ repopulation (see Supplementary material online, Figure  S13B and C).
Myeloid ET B receptor deficiency augments the chronic hypertensive response to endothelin-1 and angiotensin II
In line with an important role for the myeloid ET B receptor in protecting from the deleterious effects of ET-1, ET-1 administration into LysMET B
-/mice led to a two-to three-fold exaggerated hypertensive response to ET-1 compared with littermate control mice ( Figure 8A) .
To confirm our findings, we exposed LysMET B -/and littermate control mice to a 2-week infusion of ANG II, a model of hypertension that is ET-1 dependent. 20 Figure 8B) .
In patients with anti-neutrophil cytoplasmic antibody vasculitis different immunotherapies variably affect blood pressure and the endothelin system Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are standard therapies for patients with small vessel vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA).
Cyclophosphamide not only depletes B and T cells but also effectively depletes circulating and tissue M/ 28 ; MMF suppresses T-and B-cell function but does not deplete M/. Thus, we investigated changes in BP and the ET system following treatment in 20 patients with ANCA vasculitis: 10 received CYC as their immunosuppressive therapy whereas the other 10 received MMF. Demographics and other treatments, including corticosteroid dose, antihypertensive treatment, and the use of plasmapharesis, were similar between groups (see Supplementary material online, Table S2 ).
Baseline systolic and diastolic BP, plasma and urine ET-1 did not differ between the two groups (see Supplementary material online, Table S2 ). Interestingly, plasma ET-1 was higher in patients with ANCA vasculitis than in healthy volunteers (3.74 ± 0.38 pg/mL vs. 1.21 ± 1.2 pg/mL, P = 0.02). Whereas CYC reduced mean circulating monocyte count MMF did not (baseline vs. week 6: CYC: 0.87 ± 0.15 vs. 0.26 ± 0.17 Â 10 9 , P < 0.05; MMF: 0.77 ± 0.25 vs. 0.69 ± 0.29 Â 10 9 , P = 0.756). Cyclophosphamide treatment was associated with a greater increase in BP compared with treatment with MMF ( Figure 9A and B, P < 0.01 for CYC vs. MMF). There was a positive correlation between the change in peripheral monocyte count and the extent to which BP rose in those patients receiving CYC ( Figure 9C and D) . Plasma ET-1 fell following treatment with MMF ( Figure 9E , P < 0.001 for both weeks 0 vs. 6 and 6 vs. 12), whereas CYC treatment only led to an initial fall in plasma ET-1 (P < 0.05 for weeks 0 vs. 6). Plasma ET-1 was lower at week 12 in those treated with MMF ( Figure 9E) . Urine ET-1 fell with both CYC and MMF ( Figure 9F , P < 0.01 for CYC and P < 0.0001 for MMF for weeks 0 vs. 12) but to a greater degree with MMF (P < 0.01 for MMF vs. CYC). Flow-mediated dilation (FMD) of the brachial artery was similar at baseline between the two groups (6.7 ± 0.2 for MMF vs. 6 .6 ± 0.1% for CYC, P = 0.589). At 12 weeks, FMD had not changed in those patients receiving MMF treatment) whereas those patients receiving CYC had lower FMD in keeping with worse endothelial function (-1.2%, P < 0.05 vs. baseline).
In these same patients, we characterized M/ expression of ET A and ET B receptors and compared this to health (see Supplementary material online, Table S2 and Figure S9G and H). There were no differences in expression of the ET A receptor between the groups and in keeping with our previous data its expression was lower than that of the ET B receptor. Interestingly, patients presenting with ANCA vasculitis demonstrated reduced expression of the ET B receptor on 
their M/ compared with levels seen in health. This was normalized by treatment with MMF but further reduced following treatment with CYC.
Discussion
For the first time, we have demonstrated that the M/ ET B receptor in both mouse and humans provides a novel clearance mechanism for ET-1. Its functional importance in vivo is demonstrated by the exaggerated pro-hypertensive effect of ET-1 and ANG II in mice with a deletion of the M/ ET B receptor or following systemic M/ depletion. Interestingly, and unexpectedly, we found no evidence that ET-1 was able to polarize mouse or human M/ towards a classical proinflammatory or alternative anti-inflammatory phenotype but both displayed chemokinesis towards ET-1. Overall, these data provide us with new knowledge, and a clarification of mechanisms underlying the pathological basis of hypertension in relation to the immune and ET systems ( Figure 10) .
To date, many of the studies investigating the role of the innate immune system in the pathogenesis of, and response to, hypertension have focused on the role of T cells in relation to ANG II-mediated hypertension. [29] [30] [31] Few have examined the role of M/ and only one study relates to ET-1-mediated vascular injury. 32 Recent studies have explored the effects of altering the phenotype of bone marrowderived cells 9 or M/ 10 on hypertension and its complications, whereas others have elegantly depleted neutrophils and M/ 8 to this end.
The results of these studies are often contradictory but, nevertheless, suggest that M/ may contribute to, and protect from, hypertension. The study by Machnik et al. 7 showed that salt loading increases M/ accumulation in the subcutaneous space. These M/ are stimulated by the hypertonic environment to produce vascular endothelial growth factor C. This leads to proliferation of lymphatics. This is protective, because clodronate-mediated M/ depletion prevents the lymphatic proliferation and leads to hypertension in response to salt loading. These landmark findings support a role for M/ acting as a buffering mechanism, protecting against the development of hypertension. Our study extends beyond these, providing a mechanistic understanding of the interaction between M/ and local vascular contractility and the impact on BP. The M/ system comprises a spectrum of cell types, and depletion strategies vary in their specificity and efficacy. 33 Hence, we used two depletion models here, the CD11b-DTR (reduction in M/ number) and lysozyme M (LysM; alternation in M/ phenotype)-Cre systems. DT administration on CD11b-DTR mice achieved 90% ablation of circulating monocytes. In terms of resident cells, there was a significant reduction in renal M/ but less of an effect in the liver and spleen. Analysis of the main monocyte subsets (Gr1 1 CCR2 1 CX3CR1 2 and Gr1 2 CCR2 2 CX3CR1 1 ) demonstrated that both are equally depleted over the time course of our studies. DT administration did not deplete neutrophils. These findings are in keeping with earlier studies. 34, 35 Using the LysM-Cre system, there is functional depletion (80-100%) of mature M/ but also neutrophils. 
Additionally, this system may partially (16-20%) deplete dendritic cells (DCs), 36 an effect that is more pronounced in the CD11b-DTR mice. 35 Both CD11b-DTR mice administered DT and LysMET B -/mice were more sensitive to the pressor effects of ET-1. Taken together it is likely these effects were due to an absence of circulating monocytes and/or vascular M/. Given the acute nature of the response, we hypothesize that in control mice circulating monocytes remove the intravenously administered ET-1 to some extent thus attenuating the amount reaching the target VSMC. In contrast, the absence of this ET-1 clearance in M/-deplete mice allows more to be available to act on these cells promoting an exaggerated vasoconstrictor and so hypertensive response. There may be a contribution from DCs and neutrophils to these effects. Although there is currently no evidence that murine or human DCs are able to regulate ET-1, by its clearance or degradation, one study has shown that DCs are able to synthesize ET-1 in response to inflammatory stimuli 37 although another has suggested the opposite. 38 Interestingly, the few data on neutrophils and ET-1 suggest that these cells can both produce and degrade ET-1. 39 Our data also demonstrate that M/ are important in hypertension. We used three models of hypertension-chronic ET-1 and ANG II infusion, which are both dependent on the ET system, 20, 21, 40, 41 and a high salt diet. M/ depletion with repeated doses of DT resulted in gradual increases in both systolic and diastolic BP in chronic ET-1 and salt-dependent hypertension. Interestingly, once the DT administration was stopped (and M/ were allowed to repopulate) as well as monocyte adoptive transfer resulted in both systolic and diastolic BP returning to pre-depletion levels. This suggests that the importance of both circulating and/or organ-based M/ and future work should focus on discriminating which of these is more important here. The importance of the ET B receptor in chronic hypertension is provided by data from our mice genetically deficient for ET B on M/ alone. Here, two separate models of hypertension, chronic ET-1 and chronic ANG II infusion, elicited exaggerated rises in both systolic and diastolic BP in knockout animals compared with littermate controls.
ET-1 is considered to be pro-inflammatory, so it was surprising that it was unable to polarize M/ phenotype, at least in vitro. This was true at a range of ET-1 concentrations (10-10 000 pg/mL; mean plasma ET-1 in mice 2-3 pg/mL 42 ), whether the ET-1 was administered prior to, following or concomitantly with classical (LPS/INFc) or alternative (IL-4/IL-13) stimulation. The few data supporting a proinflammatory effect of ET-1 on M/ used immortalized M/ tumour cell lines and lacked robust methodology. 43, 44 Interestingly, and in keeping with earlier studies, 37,45 LPS/INFc stimulation of mouse M/ did increase ET-1 concentrations in the supernatant at 24 h and this was completely blocked by an inhibitor of ECE suggesting that this increase in immunoreactive ET-1 is a result of de novo production by M/.
Mouse BMDM demonstrated chemokinesis towards ET-1 and this was reduced by selective ET A antagonism and completely abrogated by selective ET B blockade. Two recent studies support our findings 46, 47 but both found that the ability of M/ to move towards ET-1 was more dependent on the ET A receptor than the ET B . Of note, both studies investigated that the role of M/ and the ET system in the setting of cancer (bladder and breast) where there may well be several different M/ phenotypes with a different balance of ET A :ET B receptors. In support of ET B -mediated chemokinesis, BMDM from LysMET B -/displayed no migration towards ET-1. This was not due to an inability to move as they retained their chemokinetic response to MCP-1. Our data showing that M/ produce ET-1 in response to an inflammatory stimulus allows us to postulate that this may in turn lead to recruitment of further M/ to the area of inflammation as a mechanism to propagate or regulate the response of the innate immune system. Thus, although M/ are not activated by ET-1 they migrate towards it and clear the peptide through ET B receptor-mediated uptake providing a novel clearance mechanism for the peptide. In EC, the ET B receptor resides within caveolae. Binding of ET-1 to endothelial ET B stimulates rapid budding and internalization of the caveolae containing the ET B receptor bound ET-1. 48 This mechanism is dynamindependent. In our in vitro studies, both mouse and human M/ removed ET-1 from their surrounding media, an effect that was significantly reduced by selective antagonism (or knockdown) of the ET B receptor but unaffected by ET A blockade. In keeping with ET-1 clearance by caveolar ET B receptors, inhibiting dynamin GTPase activity with dynasore completely prevented ET-1 removal by M/. M/ are multi-functional cells and are able to degrade peptides through the secretion of proteases as well as through the activity of the cell surface metalloprotease, NEP. 49 However, broad protease and NEP inhibition did not affect M/ ET-1 uptake.
To demonstrate the clinical relevance of our findings, we studied patients with ANCA-associated vasculitis, a potentially lifethreatening autoimmune condition. Circulating ET-1 was higher in those with vasculitis than in health, probably contributed to by systemic inflammation and endothelial dysfunction. Both MMF and CYC are standard therapies for this condition but they differ in their mechanisms of action. Whereas, MMF inhibits T-and B-cell proliferation and function, 50 CYC is directly cytotoxic and depletes not only these cells but also circulating and tissue M/. 28 In keeping with this action, we demonstrate that CYC has a tendency to reduce the circulating monocyte count by approximately 50% whereas MMF does not. Although this is an accepted measure of circulating monocytes 51 it does not account for tissue-based M/. Nevertheless, we show here that those patients receiving CYC have a greater increase in BP and deterioration in endothelial function than those receiving MMF. In part, this may be due to loss of M/-ET regulation. This is supported by the greater fall in plasma ET-1 in the MMF, but not CYC group, and the down-regulation of the M/ ET B receptor with CYC but not MMF. Thus, hypertension in CYC-treated patients may respond well to ET antagonists. This hypothesis should be explored in future clinical studies as there are few data that relate to the impact of vasculitis and its treatment on BP or vascular function-which is important because ET antagonism may have broader cardiovascular benefits. [52] [53] [54] [55] In summary, our study has identified a new interaction between M/ and the endothelin system, whereby M/ are drawn to ET-1, without any evident effect on polarization of phenotype, and clear ET-1 from the surrounding milieu. In vivo, this cellular action has a significant impact on acute vascular function and BP; importantly this pathway exerts a restraining effect on BP in chronic hypertension. Our final study strongly suggests that this system is operational in humans and therefore represents an intriguing opportunity to modulate BP and reduce cardiovascular risk in multi-system inflammatory conditions. In future, studies such as ours might lead to newer and
